KR20140125137A - Compound comprising extracts or fractions of Potentilla genus having anti-inflammation activity - Google Patents
Compound comprising extracts or fractions of Potentilla genus having anti-inflammation activity Download PDFInfo
- Publication number
- KR20140125137A KR20140125137A KR20130042928A KR20130042928A KR20140125137A KR 20140125137 A KR20140125137 A KR 20140125137A KR 20130042928 A KR20130042928 A KR 20130042928A KR 20130042928 A KR20130042928 A KR 20130042928A KR 20140125137 A KR20140125137 A KR 20140125137A
- Authority
- KR
- South Korea
- Prior art keywords
- inflammatory
- extract
- composition
- present
- fraction
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 36
- 206010061218 Inflammation Diseases 0.000 title abstract description 19
- 230000000694 effects Effects 0.000 title description 12
- 150000001875 compounds Chemical class 0.000 title description 4
- 241001092489 Potentilla Species 0.000 title 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 81
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 14
- 241000588722 Escherichia Species 0.000 claims abstract description 13
- 241000196324 Embryophyta Species 0.000 claims abstract description 10
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims abstract description 8
- 239000000419 plant extract Substances 0.000 claims abstract description 8
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 claims abstract description 7
- 235000006008 Brassica napus var napus Nutrition 0.000 claims abstract description 7
- 240000000385 Brassica napus var. napus Species 0.000 claims abstract description 7
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 claims abstract description 7
- 235000004977 Brassica sinapistrum Nutrition 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 208000027866 inflammatory disease Diseases 0.000 claims description 19
- 235000013305 food Nutrition 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 235000009569 green tea Nutrition 0.000 claims 1
- 239000000401 methanolic extract Substances 0.000 claims 1
- 239000012046 mixed solvent Substances 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 abstract description 23
- 229920006008 lipopolysaccharide Polymers 0.000 abstract description 22
- 230000004054 inflammatory process Effects 0.000 abstract description 18
- 210000002540 macrophage Anatomy 0.000 abstract description 15
- 150000003180 prostaglandins Chemical class 0.000 abstract description 8
- 229960002986 dinoprostone Drugs 0.000 abstract description 5
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract description 5
- 229940023866 safflower seed extract Drugs 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 22
- 230000002757 inflammatory effect Effects 0.000 description 22
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 20
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 17
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 16
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 15
- 238000000605 extraction Methods 0.000 description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 102100040247 Tumor necrosis factor Human genes 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 7
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 7
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- -1 IL- Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 241000222336 Ganoderma Species 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000002031 ethanolic fraction Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 102000000584 Calmodulin Human genes 0.000 description 4
- 108010041952 Calmodulin Proteins 0.000 description 4
- 240000008397 Ganoderma lucidum Species 0.000 description 4
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 4
- 208000007882 Gastritis Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 208000010668 atopic eczema Diseases 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 235000001465 calcium Nutrition 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 241000282465 Canis Species 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 3
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 3
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 3
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 240000006439 Aspergillus oryzae Species 0.000 description 2
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- 229930064664 L-arginine Natural products 0.000 description 2
- 235000014852 L-arginine Nutrition 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102100035100 Transcription factor p65 Human genes 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- WQFIAVZQVYASHZ-BYPYZUCNSA-N (2s)-5-(diaminomethylideneamino)-2-(hydroxyamino)pentanoic acid Chemical compound NC(=N)NCCC[C@H](NO)C(O)=O WQFIAVZQVYASHZ-BYPYZUCNSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SKLHQIMWCOGGKH-UHFFFAOYSA-O 2-[2,3-dimethyl-6-(5-phenyl-2H-tetrazol-1-ium-1-yl)phenyl]-1,3-thiazole Chemical class CC1=C(C(=C(C=C1)[N+]=1NN=NC=1C1=CC=CC=C1)C=1SC=CN=1)C SKLHQIMWCOGGKH-UHFFFAOYSA-O 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitrogen oxide(NO) Natural products O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 229930189092 Notoginsenoside Natural products 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 244000040141 Potentilla sundaica Species 0.000 description 1
- 241000619274 Potentilla supina Species 0.000 description 1
- 241000208476 Primulaceae Species 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 235000005733 Raphanus sativus var niger Nutrition 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 240000001970 Raphanus sativus var. sativus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000201895 Salicornia Species 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 241000736285 Sphagnum Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000001727 Tropicoporus linteus Species 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012152 bradford reagent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002036 chloroform fraction Substances 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000008738 huangbai Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000005550 inflammation mediator Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000037916 non-allergic rhinitis Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003254 radicals Chemical group 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000004552 water soluble powder Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention is applied to a composition having an anti-inflammatory activity comprising a plant extract of the genus Escherichia or a fraction thereof. More specifically, the present invention relates to a composition having anti-inflammatory activity, which comprises a safflower seed extract and a canola extract, or fractions thereof, which are plants of the genus Escherichia.
The present invention relates to a method for the production of nitric oxide (NO), prostaglandin (prostaglandin E2, PGE2), which is secreted from a macrophage by lipopolysaccharide (LPS) Generation or the like, thereby being useful for preventing or treating various inflammation.
Description
The present invention relates to a composition having an anti-inflammatory activity comprising a plant extract of the genus Escherichia or a fraction thereof. More specifically, the present invention relates to a composition having anti-inflammatory activity, which comprises a safflower seed extract and a canola extract, or fractions thereof, which are plants of the genus Escherichia.
Inflammation is one of the damage of tissue, external stimulation or defense of biological tissues against various infectious agents. Enzyme activation, inflammation mediator secretion, cell infiltration due to organic interactions of various inflammatory mediators and various immune cells in blood vessels and body fluids And a series of complex pathologies such as fluid exudation, circulatory disturbances, tissue degeneration and hyperplasia. In the process of inflammatory reaction, macrophages are collected at the wound area at the initial stage and attack the invading bacteria. After that, plasma accumulates on the injured area and blood flow is increased, resulting in external symptoms such as fever, erythema, edema and pain . If the inflammatory reaction continues or occurs excessively, it progresses to a major pathological condition (irritable allergic disease, chronic inflammatory disease) of the disease, resulting in serious abnormal disorder.
Nonsteroidal anti-inflammatory drugs (NSAIDS), a widely used agent for the treatment of most inflammatory diseases, are produced from arachidonic acid called prostaglandin, called cyclooxygenase (COX) Inhibition of the enzymatic activity involved in the biosynthesis of the glycosaminoglycans, exhibits an anti-inflammatory action. In addition to the main therapeutic effect, it causes severe adverse effects such as gastrointestinal disorders, hepatic disorders, renal diseases and the like. Therefore, the development of a novel anti-inflammatory analgesic agent that is excellent in anti-inflammatory efficacy is widely demanded because there is no side effect and it is not difficult to use for a long period of time. This is why research on material development through the verification of efficacy from natural resources is being activated recently.
Various biochemical phenomena are involved in the cause of inflammation in living body. Macrophage is a cell with various functions. It produces various cytokines and NO by chemical stimulation and plays an important role in the inflammation reaction. In particular, inducible nitric oxide synthase (iNOS) expressed by macrophage-stimulated cytokines such as lipopolysaccharide (LPS) and interferon gamma and TNF-α produces large amounts of nitrogen oxides (NO) over a long period of time. These oxidative stresses are known to promote NFκB activity, a transcription factor of inflammatory responses inhibited by IκB. Activated NFκB is known to migrate to the nucleus and promote gene expression that induces inflammatory responses such as iNOS, COX-2, and several cytokines such as IL-1β and TNF-α. When these factors are inhibited, (Baeuerle et al., Annu. Rev. Immunol., 12: 141-179, 1994).
Nitrogen oxides (NO) are produced from L-arginine by three major nitrogen oxide synthase (NOS) isomers, neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS). While nNOS and eNOS are regulated by Ca2 + / calmodulin, iNOS is regulated at the transcriptional level by inflammatory stimuli such as interleukin, interferon, and LPS. NO produced by nNOS or eNOS plays a normal physiological function such as vasodilation, neurotransmission, cell destruction to pathogen, etc. However, overexpressed NO produced by macrophages in iNOS is involved in various pathophysiological And reacts with superoxide to form peroxynitrite, which acts as a powerful oxidant to damage cells, activates NFκB in macrophages activated by inflammatory stimuli, , Cancer, atherosclerosis, and the like.
Prostaglandins are unsaturated fatty acid derivatives containing 20 carbons with a cyclic structure. They are chemical mediators mainly involved in chronic inflammatory diseases and are also involved in autoimmune diseases such as asthma. Prostaglandins are biosynthesized by COX, which has two isomers, COX-1 and COX-2. COX-1 is a constant enzyme present in tissues such as the stomach or kidney, and is involved in maintaining normal homeostasis, whereas COX-2 is a transient and rapidly expressed expression in cells by cytokines or cytokines in inflammation or other immune responses do. NSAIDs used in the treatment of chronic inflammatory diseases such as acute or rheumatoid arthritis are known to exhibit various side effects such as gastrointestinal disorders as mentioned above by inhibiting COX-1 enzyme as well as inhibiting COX-2 enzyme.
Therefore, when a substance that inhibits the production of tumor necrosis factor (TNF-α) and nitrogen oxide (NO), inhibits prostaglandin production, or inhibits the production of IL-1β is searched, will be.
On the other hand, the plants of the wing of the Yangmyeong family are the perennial plants belonging to the primrose family. They are mainly grown in sunny mountainous areas, grasslands and sometimes high mountains. They are distributed in various parts of Korea, including Samhwacho, , Watery grasses, and three-leafed rice blossoms. Twenty-four from Salicornia (Potentilla kleiniana , orchid ) grows in a humid place, height is 20 ~ 60cm, and the lower half grows at an angle. The roots are palm-like compound leaves with long petiole, three leaves are running on the stem, and petiole becomes shorter as it goes up. It is used for the juice of juvenile food. It is called as a snake (snakes), and it is prescribed for fever, cold, sore throat, boil, eczema etc. Potentilla supina ) is also known as a spotted gabi , grows in the field and is about 50cm in height. The stem is gathered tightly and the lower side grows at an angle to the side, straight up, the branches are staggered, the leaves are staggered and there are petiole. Fruits are round oaks, ripened in September-October, no hairs, young stems and leaves are used for food.
However, there has been no study or report on the effect of the above-described extracts or fractions thereof on the inflammation. Accordingly, the present inventors have completed the present invention by confirming that Saffron ginseng and Ganoderma lucidum extract, or fractions thereof, of the plants of the genus Escherichia can inhibit the production of nitrogen oxides or inhibit the production of prostaglandins.
The present invention provides a composition having an anti-inflammatory activity comprising a plant extract of the genus Escherichia or a fraction thereof.
The present invention relates to a composition having an anti-inflammatory activity comprising a plant extract of the genus Escherichia or a fraction thereof.
The present invention also relates to a pharmaceutical composition for preventing or treating an inflammatory disease comprising the above composition as an active ingredient.
The present invention also relates to a cosmetic composition and a food composition for preventing or improving an inflammatory disease containing the composition as an active ingredient.
The water extracts of the Japanese radish and the extracts or fractions thereof of the present invention inhibit mRNA expression of TNF-α, IL-1β which are inflammatory cytokines secreted from macrophages by lipopolysaccharide (LPS) (NO), prostaglandin (prostaglandin E2, PGE2), and the like, thereby preventing or treating various inflammation.
Figure 1 relates to the efficacy of ethanol fractions for LPS-induced iNOS and COX-2 protein expression.
Fig. 2 relates to the efficacy of the SARS ethanol fraction on LPS-induced inflammatory mRNA expression.
Figure 3 relates to the efficacy of the L. angustifolia ethanol fraction for LPS-induced inflammatory mRNA expression.
Figure 4 relates to the efficacy of the ethanol fraction for LPS-induced NF-kB nuclear translocation.
The present invention relates to a composition having an anti-inflammatory activity comprising a plant extract of the genus Escherichia or a fraction thereof.
The plants of the Saccharomyces cerevisiae include, but are not limited to, alfalfa or canola seedlings.
In order to prepare the extract of Sorghum ganoderma L. and Canola ganoderma L. extract of the present invention, water, C1-C3 alcohol or a mixture thereof may be used as an extraction solvent, and extraction with methanol or ethanol may be used. It is not. The amount of the extraction solvent may be 2 to 20 times by weight, and may be 5 to 10 times by weight, relative to the dry weight of the plant, but is not limited thereto.
Examples of the method for extracting the plant include a method using an extraction device such as hot water extraction, immersion extraction, supercritical extraction, subcritical extraction, high temperature extraction, high pressure extraction, reflux cooling extraction and ultrasonic extraction, or adsorption resin including XAD and HP- A method using a conventional extraction method of the art can be used. It may be heated, refluxed or extracted at room temperature, but is not limited thereto. The extraction number is preferably 1 to 5 times, more preferably 3 times, but is not limited thereto. It may be extracted once to five times by an ultrasonic extraction method. The temperature for extraction is preferably from 10 to 100 ° C, more preferably room temperature, but is not limited thereto. The extraction time may be from 1 day to 7 days, and may be from 3 days to 7 days, but is not limited thereto.
The extract can be concentrated under reduced pressure, but is not limited thereto. The vacuum concentration may be performed using a vacuum rotary evaporator, but the present invention is not limited thereto. The drying may be carried out under reduced pressure, vacuum drying, boiling, spray drying, room temperature drying or freeze drying, but is not limited thereto.
The syrups of the present invention can be obtained by suspending a water-soluble extract of Sambacho or Phellinus linteus in water, and then sequentially fractionating the extract with a solvent having a different polarity. The solvent may be any solvent selected from the group consisting of ethanol, EtOH, hexane, chloroform, ethyl acetate, EtOAc, and mixtures thereof. In one embodiment of the present invention, all the above fractions exhibited activity, but the ethanol fraction showed the highest activity.
The term "anti-inflammatory activity" as used herein refers to inhibiting inflammation, and the term " inflammation " as used herein means the pathological condition of abscess formed by the invasion of external bacteria. Inflammation reaction is a biological defense reaction process for repairing and regenerating damage caused by invasion that brings about a fundamental change in the cell or tissue of a living body. It is a process of damaging tissues (cells) or infecting external sources (bacteria, fungi, Allergen-inducing substances), various inflammatory mediators and immune cells are involved in local blood vessels and body fluids, and a series of complex physiological responses such as enzyme activation, inflammatory mediator secretion, body fluid infiltration, cell migration, and tissue destruction, And fever pain. In normal cases, the inflammatory reaction removes the external infectious agent and regenerates the damaged tissue to regenerate the organism's function. However, if the antigen is not removed or the internal substance causes the inflammatory reaction to occur excessively or continuously, the major pathological condition of the disease (irritable disease, Chronic inflammation), and become obstacles in the treatment process such as transfusion, drug administration, or organ transplantation.
The extract of the present invention or the extract of Ganoderma lucidum extract or its fraction is not an artificially synthesized compound but has advantages of safety, toxicity and side effects because it is based on the components obtained from natural extracts, so that it can be taken for a long time. The composition may be used not only for humans but also for animals such as monkeys, dogs, cats, rabbits, guinea pigs, rats, mice, cattle, sheep, pigs,
Accordingly, the present invention can be used as a pharmaceutical composition for preventing or treating inflammatory diseases, which comprises as an active ingredient an extract of Samcheonchon or P. ganoderma extract or a fraction thereof, and the composition can be treated to prevent or treat an inflammatory disease.
The " inflammatory disease " of the present invention is defined as any condition specified by a local or systemic bio-defense response to an external physical or chemical stimulus or infection of an external infectious agent such as a bacterium, a fungus, or a virus. This reaction is associated with activation of various inflammatory mediators and enzymes associated with immune cells (such as iNOS, COX-2, etc.), secretion of inflammatory mediators such as NO, TNF-a, IL-6, IL- , Body fluid infiltration, cell migration, tissue destruction, and is manifested externally by symptoms such as erythema, pain, edema, fever, deterioration or loss of specific function of the body. The inflammatory disease may be acute, chronic, ulcerative, allergic or necrotic, so long as it is included in the definition of inflammatory diseases as above, it may be acute, chronic, ulcerative, allergic, Whether it is necrotic or not. Specifically, the inflammatory diseases include asthma, allergic and non-allergic rhinitis, chronic and acute rhinitis, chronic and acute gastritis or enteritis, ulcerative gastritis, acute and chronic nephritis, acute and chronic hepatitis, chronic obstructive pulmonary disease, Inflammatory bowel syndrome, inflammatory pain, migraine headache, headache, back pain, fibromyalgia, fascia disease, viral infection (e.g., C type infection), bacterial infection, fungal infection, burn, wound due to surgical or dental surgery, Prostaglandin E Overdose Syndrome, atherosclerosis, gout, arthritis, rheumatoid arthritis, ankylosing spondylitis, Hodgkin's disease, pancreatitis, conjunctivitis, iritis, scleritis, uveitis, dermatitis, eczema, atopic inflammation, acne, multiple sclerosis .
The term "prophylactic" of the present invention refers to any action that inhibits or delays the onset of the disease by the administration of a composition comprising the samphanuum or canine ganoderma extract or fractions thereof according to the present invention.
The term "treatment" of the present invention refers to any action that improves or alleviates the symptoms of the disease by administration of a composition containing the extract or the extract of Panax notoginsenoside or extract thereof according to the present invention.
In the present invention, RAW 264.7 macrophage cells were tested for the inhibitory effect on the production of nitrogen oxides (NO), prostaglandin E2 (PGE2) and inflammatory mRNA expression , And cytotoxicity evaluation experiments were performed.
As a result of the measurement, the extract of Radix Salvia miltiorrhizae and Ganoderma lucidum extract or its fractions were not cytotoxic (see Table 1). In addition, it was confirmed that production and secretion of inflammatory cytokine and chemokines NO and PGE2 were markedly inhibited (see Tables 2 to 3).
In the present invention, the inflammatory factor involved in the inflammatory reaction is nitric oxide (NO). NO is produced by nitric oxide synthase (NOS) from L-arginine through the intermediate metabolite hydroxyarginine and NO and citrulline. NO has a biological activity and acts on the vascular system in vivo to mediate vasodilation, platelet adhesion and aggregation, neurotransmission, and digestive organ exercise. In addition, NO has been shown to play a role in several metabolic regulatory and physiological actions (neurotransmission, blood clotting, blood pressure control, immunity against cancer cells, etc.) and is also produced in inflammatory cells as well as nonimmune cells, .
In general, NO is present in the form of gas in the atmospheric state, and because it is a free radical structure, it is not only poisonous but also has a half-life of 6 to 10 seconds, which is very unstable and is known to be rapidly converted into stabilized end products NO 3 and NO 2 have.
On the other hand, NO synthase involved in the NO synthesis (NOS) is divided into calcium (Ca 2 +) or calmodulin (camodulin) significantly cNOS (constitutive NOS) and iNOS (inducible NOS) in accordance with whether or not dependence. cNOS is dependent on calcium or calmodulin, mainly in the brain, epithelial cells, neutrophils, and gastric mucosal cells. iNOS is independent of calcium or calmodulin, and iNOS is present in macrophages, hepatocytes, cancer cells, IFN-γ, TNF-α, and the like, and bacterial LPS (lipopolysaccharide), an endotoxin. Because of the activation of cyclooxygenase-2 (COX-2) by the stimulation, prostaglandin (PGs), which is an inflammatory mediator, is produced. Therefore, iNOS expression and COX-2 expression are closely related to each other. It also affects COX-2 expression. Inflammatory diseases caused by these inflammatory reactions include, in addition to arteriosclerosis, gastritis, colitis, arthritis, nephritis, hepatitis, cancer or degenerative diseases.
The pharmaceutical composition for prevention or treatment of inflammatory diseases, including the sphagnum ganoderma or the extract of Aspergillus oryzae, or fractions thereof, according to the present invention may be administered to mammals such as rats, mice, livestock and humans in various routes. All modes of administration can be expected and can be administered, for example, by oral, rectal, or intravenous, intramuscular, subcutaneous, intracerebral or intracerebroventricular injection, Lt; / RTI >
The amount of the pharmaceutical composition for preventing or treating inflammatory diseases used in the present invention should be a pharmaceutically effective amount. The term "pharmaceutically effective amount" as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and the effective dose level will vary depending on the species and severity, age, sex, The type of drug, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. The effective amount may vary depending on the route of treatment, the use of excipients and the likelihood of use with other medicaments, as will be appreciated by those skilled in the art.
The pharmaceutical treatment forms of the composition for preventing or treating inflammatory diseases of the present invention may be used in the form of their pharmaceutically acceptable salts and may also be used alone or in combination with other pharmaceutically active compounds.
The pharmaceutical compositions for the prevention or treatment of inflammatory diseases of the present invention may be prepared into pharmaceutical formulations using methods well known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to the mammal . In the preparation of the formulations, the active ingredient may be mixed with or diluted with the carrier, or enclosed in a carrier in the form of a container.
Accordingly, the pharmaceutical composition for preventing or treating inflammatory diseases according to the present invention can be administered orally or parenterally in the form of oral, granule, tablet, capsule, suspension, emulsion, syrup, aerosol or the like, oral preparation, And may further comprise suitable carriers, excipients and diluents conventionally used in the production of the composition.
Examples of carriers, excipients and diluents that can be included in the pharmaceutical composition of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used.
Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose ), Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used.
Examples of the liquid preparation for oral administration include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweetening agents, have.
Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.
In another aspect, the present invention relates to a cosmetic composition comprising, as an active ingredient, a composition comprising samphanaceae or extract of Aspergillus oryzae or fractions thereof. The cosmetic composition according to the present invention may be formulated into a cosmetic, a gel, a water-soluble powder, a fat-soluble powder, a water-soluble liquid, and an essence in a cream by adding a pH adjusting agent, a flavoring agent, an emulsifier, have.
In addition, in another aspect, the present invention provides a food composition for improving inflammatory diseases, which comprises as an active ingredient an extract of Sam Roiot bean or L. anthracis extract or a fraction thereof.
The food composition of the present invention includes forms such as pills, powders, granules, infusions, tablets, capsules or liquid preparations. Foods to which the composition of the present invention can be added include, for example, beverages, gums, tea, vitamins And health supplement foods.
There are no particular restrictions on other components other than the composition containing the above-described Sam-Nam-gwang or Ganoderma lucidum extract or its fractions as an essential ingredient that can be contained in the food composition of the present invention. The composition of the present invention is not limited to a variety of herbal medicine extracts, Natural carbohydrates and the like as additional components.
The food composition may further include one or more herbal medicine extracts selected from the group consisting of Sanchosan, Gongsuanggang, Pungyoung, Huangbai, Seokchangpo,
The food supplementary additives may further include flavors, flavors, colorants, fillers, stabilizers and the like which are commonly used in the art.
Examples of such natural carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above .
In addition to the above, the food composition of the present invention may contain various nutrients, vitamins, minerals (electrolytes), flavors of synthetic flavors and natural flavors, colorants and heavies (cheese, chocolate etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. In addition, it may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks. These people can be used independently or in combination.
In addition, the food composition of the present invention may be any one of meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, Lt; / RTI >
BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the present invention will be described in detail with reference to the following examples. However, the following examples are intended to illustrate the contents of the present invention, but the scope of the present invention is not limited to the following examples. Embodiments of the present invention are provided to more fully describe the present invention to those skilled in the art.
< Example 1> Experimental method
1. Cell culture
RAW 264.7 cells were cultured in DMEM (Dulbecco's modified Eagle's medium, Gibco, New York, USA) containing 10% FBS and penicillin (100 μg / ml) and streptomycin And cultured under the condition. RAW 264.7 cells were pretreated with various concentrations (10, 20, and 40 μM) of the sample solution for 1 hour, treated with LPS and cultured for 24 hours.
2. MTT assay Cytotoxicity test
To determine the degree of toxicity of the cells, MTT (dimethyl thiazolyl diphenyl tetrazolium salt, a type of tetrazole, Sigma Chemical Co., St. Louis, MO, USA) was used. Cells were equally divided into 96-well plates (353077, falcon ™, USA) at 1 × 10 5 cells / ml and cultured for 24 hours. After washing with PBS (Phosphate buffer saline, Bioneer Co., Deajeon, Korea), 100 μl of H 2 O 2 (Hydrogen peroxide solution, BBC Biochemical, Washington, USA) After incubation for 45 minutes, the supernatant was removed, washed twice with PBS buffer, and then 200 μl of the medium was injected for another 24 hours. After addition of 50 μl of 5 mg / ml MTT reagent, the supernatant was removed. 100 μl of DMSO (dimethyl sulfoxide, Sigma Chemical Co., St. Louis, Mo., USA) was added and incubated at 540 nm in an ELISA microplate reader The survival rate was calculated by measuring the absorbance with a Power Wave 340, Bio-Tek Instruments Co., USA).
3. Nitric oxide ( NO ) Quantity measurement
The amount of NO produced from RAW 264.7 cells was measured by using Griess reagent [1% (w / v) sulfanilamide in 5% (v / v) phosphoric acid and 0.1% (w / v) naphtylethylenediamine- As the form of NO 2 - . Griess reagent was mixed with 100 쨉 l of each well and reacted on a 96-well plate for 10 minutes, and the absorbance was measured at 540 nm.
4. PGE 2 Measurement of quantity
Cells from the cells treated with the sample and control were taken and the amount of PGE 2 was quantified according to the instructions of the assay design kit (Amersham pharmacia Biotech Co., USA).
5. Western blot exam
Cells treated with the sample and the control group were lysed with lysis buffer PRO-PREP (Intron Biotechnology Co., Sungnam, Korea), centrifuged and the supernatant was taken to extract the proteins. The protein concentration of the supernatant was quantified using a Bradford reagent to obtain 30 μg of the protein. The extracted protein was electrophoresed on a 10% SDS-polyacrylamide gel and the gel protein was blotted with PVDF membrane. (Santa Cruz, CA, USA), COX-2 (Santa Cruz, Calif., USA) and P65 (Santa Cruz, CA, USA) at a ratio of 1: 1000 after 90 minutes of blotting with 5% USA), PARP-1 (Santa Cruz, CA, USA), α-tubulin (Santa Cruz, CA, USA) and β-actin And washed three times at intervals of 10 minutes. The second antibody (iNOS-Rabbit, COX-2-Goat, P65-Rabbit, PARP-1-Rabbit and α-tubulin-mouse, β-actin-mouse) was left at room temperature for 1 hour at 1: -TBS three times at 10-min intervals and then developed with chemiluminescence (Gel logic 2200 PRO, Carestream Molecular Imaging Co., USA).
6. RT - PCR exam
Total cellular RNA was extracted according to the kit protocol using Easy Blue ® kits (IntronBiotechnology). 1 μg of RNA was reverse transcribed using MuLV reverse transcriptase, 1 mM dNTP and 0.5 μg / μL of oligo (dT 12 -18 ) in each sample to obtain cDNA. A total volume of 25 μL samples containing 1 unit of Taq DNA polymerase, 0.2 mM dNTP, X10 reaction buffer and 100 pmol of 5 'and 3' primers was added to the cDNA using thermal cycler (Perkin Elmer Cetus, Foster City, CA, USA) And then subjected to PCR analysis [Takara thermal cycler dice (Takara Bio Inc., Japan)].
The primer information is as follows:
1. iNOS (55 C, 50 CYCLE)
Forward primer: 5'-CATGCTACTGGAGGTGGG TG-3 '
Reverse primer: 5'-CATTGATCTCCGTGACAGCC-3 '
2. COX-2 (55 C, 50 CYCLE)
Forward primer: 5'-GGAGAGACTATCAAGATAGT-3 '
Reverse primer: 5'-ATGGTCAGTAGACTTTTACA-3 '
3. TNF-α (55 ° C, 50 CYCLE)
Forward primer: 5'-AGCACAGAAAGCATGATCCG-3 '
Reverse primer: 5'-CTGATGAGAGGGAGGCCATT-3 '
4. IL-6 (55 C, 50 CYCLE)
Forward primer: 5'-GAGGATACCACTCCCAACAGACC-3 '
Reverse primer: 5'-AAGTGCATCATCGTTGTTCATACA-3 '
5. IL-1 [beta] (55 [deg.] C, 50 CYCLE)
Forward primer: 5'-TGCAGAGTTCCCCAACTGGTACATC-3 '
Reverse primer: 5'-GTGCTGCCTAATGTCCCCTTGAATC-3 '
[Beta] -actin (55 [deg.] C, 50 CYCLE)
Forward primer: 5'-ATCACTATTGGCAACGAGCG-3 '
Reverse primer: 5'-TCAGCAATGCCTGGGTACAT-3 '
7. Statistical analysis
The values of the test values were expressed as mean ± SD, and the analysis was significant with Student's t- test.
< Example 2> Experimental results
One. RAW 264.7 Cytotoxicity of macrophages
Prior to identifying the anti - inflammatory effects of the samples, the MTT assay was performed to exclude the possibility of inhibiting the inflammatory mediators from toxic effects on RAW264.7 cells. As shown in Table 1, all samples showed no toxicity at a concentration of 100 μg / ml. The following Table 1 relates to cytotoxicity in various fractions.
2. RAW In 264.7 macrophages Nitric oxide Generation inhibitory effect
The amount of NO produced in the culture of RAW264.7 cells activated by LPS at a concentration that does not show cytotoxicity as a result of MTT assay was measured using a grease reagent. When the viablity of Lactobacillus crassiflora and Lactobacillus farina was decreased to less than 80% at 10 μg / ml or more, the experiment was carried out at 10 μg / ml or less. The inhibition of NO formation was observed in all samples except chloroform fraction. The inhibition effect of NO production by Samcheoncho ethanol, canola gabi ethanol and canine gabi ethyl acetate fraction was good, but it can not be judged to be remarkably superior to other samples To confirm the inhibitory effect of other inflammatory metabolites. The following Table 2 relates to the efficacy of the various fractions on LPS-induced NO production.
3. RAW In 264.7 macrophages PGE 2 Generation inhibitory effect
Samples were confirmed to inhibit the production of PGE 2 , another inflammatory metabolite induced by LPS, in the extract fraction. Ethanol from Samcheoncho and Ganbang ethanol from dogs were effective. In the previous NO assay and the results, considering the stability as a health functional food, the experiment was carried out by choosing Samchoanchoa ethanol and Canola gabi ethanol. Table 3 below shows LPS-induced PGE 2 RTI ID = 0.0 > production. ≪ / RTI >
4. RAW In 264.7 macrophages iNOS And COX -2 protein Expression inhibition effect
The inhibitory effects of iNOS and COX-2, which are enzymes involved in the production of NO and PGE 2 , were inhibited by ethanol and dextrin ethanol. LPS-induced iNOS and COX-2 protein expression was inhibited by the sample. β-actin was used as an internal control (see FIG. 1).
5. RAW 264.7 Inflammation in macrophages mRNA Expression inhibition effect
Inhibition of mRNA expression of iNOS, COX-2 and TNF-α, IL-1β, and IL-6, which are inflammatory cytokines, was confirmed by ethanolamine. It was confirmed that LPS-induced inflammatory mRNA expression was inhibited by the sample in a concentration-dependent manner (see FIG. 2).
Inhibition of mRNA expression of iNOS, COX-2 and the inflammatory cytokines TNF-α, IL-1β, and IL-6 was observed in canine gabi ethanol. It was confirmed that the remaining mRNA expression of LPS-induced inflammatory mRNA was inhibited by the sample in a concentration-dependent manner except for IL-6 (see FIG. 3).
6. RAW In 264.7 macrophages NF -κB translocation into the nucleus
The inhibition of translocation of p65, a subunit of NF-κB into the nucleus, was confirmed by ethanol and deoxyribonucleic acid. The translocation of p65 into the nucleus induced by LPS was inhibited by the sample in a concentration-dependent manner. PARP and α-tubulin were used as internal controls for nuclear and cytoplasm, respectively (see FIG. 4).
Claims (9)
Wherein the plant of the genus Escherichia is a green tea or a canola.
Wherein the extract is a water extract or a methanol extract of a plant of the genus Escherichia.
Wherein the fraction is a fraction using a solvent selected from the group consisting of ethanol, chloroform, hexane, ethyl acetate, and a mixed solvent thereof.
Wherein the plant extract in the genus Paracetamus or a fraction thereof suppresses the production of nitrogen oxides (NO).
Wherein said extract of the genus Escherichia or a fraction thereof inhibits the production of prostaglandin E2 (PGE2).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130042928A KR20140125137A (en) | 2013-04-18 | 2013-04-18 | Compound comprising extracts or fractions of Potentilla genus having anti-inflammation activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130042928A KR20140125137A (en) | 2013-04-18 | 2013-04-18 | Compound comprising extracts or fractions of Potentilla genus having anti-inflammation activity |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20140125137A true KR20140125137A (en) | 2014-10-28 |
Family
ID=51995082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR20130042928A KR20140125137A (en) | 2013-04-18 | 2013-04-18 | Compound comprising extracts or fractions of Potentilla genus having anti-inflammation activity |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20140125137A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107550815A (en) * | 2017-09-18 | 2018-01-09 | 上海家化联合股份有限公司 | A kind of maize seed extract and its application in skin preparations for extenal use |
KR102421900B1 (en) * | 2021-04-02 | 2022-07-19 | 인포보스 주식회사 | Composition for Anti-inflammation Using an Extract of Scutellaria indica var. coccinea |
KR102474576B1 (en) * | 2022-03-03 | 2022-12-06 | 농업회사법인 주식회사 반디 | Eco-friendly feed composition containing salad vegetable by-products and lactic acid bacteria |
-
2013
- 2013-04-18 KR KR20130042928A patent/KR20140125137A/en active Search and Examination
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107550815A (en) * | 2017-09-18 | 2018-01-09 | 上海家化联合股份有限公司 | A kind of maize seed extract and its application in skin preparations for extenal use |
KR102421900B1 (en) * | 2021-04-02 | 2022-07-19 | 인포보스 주식회사 | Composition for Anti-inflammation Using an Extract of Scutellaria indica var. coccinea |
KR102474576B1 (en) * | 2022-03-03 | 2022-12-06 | 농업회사법인 주식회사 반디 | Eco-friendly feed composition containing salad vegetable by-products and lactic acid bacteria |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101715274B1 (en) | Composition containing extract or fractions of Chrysanthemum indicum L. for treating, improving or preventing inflammatory disease | |
KR101172595B1 (en) | A composition comprising the extract of Physalis alkekengi var. francheti Masters Hort as an active ingredient for preventing and treating inflammatory disease | |
KR100825041B1 (en) | Composition for treatment or prevention of inflammatory diseases | |
KR101026528B1 (en) | Compositions for prevention and treatment of inflammatory diseases containing the extracts of seaweeds as an active ingredient | |
KR20100122333A (en) | Compositions for the prevention and treatment of obesity, hyperlipidemia, atherosclerosis, fatty liver, diabetes mellitus or metabolic syndrome comprising extracts or fractions of glycine max leaves as an active ingredient | |
KR101469325B1 (en) | Composition comprising an extract of combined crude drug including Xanthium strumarium L. for preventing and treating inflammatory disease or allergic disease | |
KR101558524B1 (en) | Pharmaceutical composition for the prevention and treatment of thromboembolism comprising mixture extracts of phellunus baumii and salvia miltiorrhiza | |
KR101618116B1 (en) | Composition of extracts of Arctium lappa or compounds isolated therefrom for preventing, improving or treating obesity or obesity-related disease | |
KR20140125137A (en) | Compound comprising extracts or fractions of Potentilla genus having anti-inflammation activity | |
KR101567573B1 (en) | Composition comprising extracts of Codonopsis lanceolata or compounds isolated therefrom for preventing, improving or treating obesity or obesity-related disease | |
CN108367039B (en) | Composition for treating or preventing liver disease comprising Citrullus spinosa extract as active ingredient | |
KR101292931B1 (en) | Composition Comprising Hedyotis diffusa extract for prevention or treatment of nonalcoholic fatty liver disease | |
KR101557934B1 (en) | Composition comprising extracts of Codonopsis lanceolata or compounds isolated therefrom for preventing, improving or treating obesity or obesity-related disease | |
EP3025721B1 (en) | Pharmaceutical composition for preventing or treating asthma comprising pistacia weinmannifolia j. poiss. ex franch extract or fraction thereof | |
KR20160079269A (en) | Anti-inflammatory pharmaceutical composition and health functional food containing artemisia fermentation extract | |
KR101857774B1 (en) | Composition for inhibiting COX-2 and iNOS Aster yomena extract or fractions thereof | |
KR101987677B1 (en) | Composition comprising extracts of Lathyrus genus having anti-inflammation activity | |
KR20190046245A (en) | Composition for preventing, improving or treating liver disease comprising fermented liquor of aged sprout ginseng extract as effective component | |
KR102191165B1 (en) | Anti-inflammatory composition using an extract of radish root, etc. | |
KR101448355B1 (en) | Composition comprising an extract of Juncus effusus L. var. decipiens Buchen. for preventing and treating inflammatory disease or allergic disease | |
KR101925724B1 (en) | Anti-inflammation Composition Using an Extract of Scirpus tabernaemontani | |
KR20110109558A (en) | A composition comprising the extract of arctium lappa linne for treating or preventing vascular disease | |
KR101373173B1 (en) | Composition comprising an extract of combined crude drug for preventing and treating inflammatory disease or allergic disease | |
KR20140142516A (en) | A composition comprising the extract of Bupleurum falcatum (BF) and Physalis alkekengi var. francheti (PAF) as an active ingredient for preventing and treating inflammatory disease | |
KR101052067B1 (en) | Inflammatory disease prevention or treatment composition containing wild vegetable extract as an active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment |